Research on Sulfur Mustard

DermDefense Inc History – Graham Paper, Rutgers Paper

In 2006 the founders of DermDefense Inc., Neal Andrews and Sandra Chansler, were approached by Dr. John S. Graham, Ph.D. of the US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD. after hearing about the SM-1997 Formulation’s ability to heal difficult wounds. This formulation was developed by Sandra Chansler.

Dr. Graham was funded by the National Institute of Health and the Department of Defense to find a treatment program for the Management of Cutaneous Sulfur Mustard Gas Injuries. He was curious about whether the SM-1997 Formulation would work on these types of injuries.

Three years and approximately five million dollars later, the results of this study were published in Toxicology, Vol. 263 Issue 1 Sept 2009. [Graham JS, Stevenson RS, Mitcheltree LW, Hamilton TA, Deckert RR, Lee RB, and Schiavetta AM.  Medical management of cutaneous sulfur mustard injuries. Toxicol.] Fill out our contact form to receive the password to our Studies page.

In conjunction with Dr. Graham’s work, collaboration with Dr. Doug Oliver at the Technology Laboratory, Porton Down, Salisbury United Kingdom helped support his claims. SM-1997 was the most effective product (compared to twenty-two other products tested) and was reviewed by the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD). See our timeline.

Study Results

These results – that SM-1997 promotes wound healing – have been discussed in presentations around the world:

• Bioscience Meeting 2008 – Germany and the Bioscience Meeting 2008 – Baltimore, MD
• XXXIV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 2014 – Brussels, Belgium
• Academy of Military Medical Science, Medical Unit, Armed Forces, WUXI, Jiangsu Province, China. 
• Also referenced in the Chinese Journal of Traumatology, Mechanism and Treatment of Sulfur Mustard Induced Cutaneous Injury. Author: Tian-Yi Gu, Beijing

DermDefense, Inc. has worked with major universities such as Rutgers University on a corneal mustard-induced injury and SM-1997 proved to be the most effective product to prevent corneal breakdown. Fill out our contact form to receive the password to our Studies page.

DermDefense, Inc. also completed work at KSU University. After the publication in Toxicology (Exhibit A), DermDefense, Inc. was approached by a Director at the Defense Threat Reduction Agency (DTRA), who is now with the SEC US ARMY DEVCOM ECBC at Edgewood. He encouraged DermDefense, Inc. to apply for grant funding to complete the required research for SM-1997 to be approved by the FDA as a drug for the treatment of sulfur mustard injury. (Currently, there is no approved product for this injury).

After a time and cost assessment, it was decided that private funding for the SM-1997 approval process would reduce costs by more than fifty percent and reduce approval time to approximately one year.

A Stellar Team

DermDefense, Inc. has assembled a high-level team of professionals to guide this project through FDA approval and ensure its success. We are well-connected within the chemical and biological communities in the US government and have gained their support for the value and use of the SM-1997 Formulation.

SM-1997 continues to increase its audience of champions because it is effective and affordable, and its easy-to-use spray-on application makes it simple to apply.

DermDefense, Inc. is very confident that our studies will be successful.  The chief scientist conducting the safety and effectiveness studies has the experience and expertise to ensure studies are conducted correctly and professionally.  Our carefully assembled team of qualified contractors, medical partners, manufacturing, and regulatory compliance partners are working closely with our executive team to meticulously guide this life-changing product through approval.

SM-1997 is a sound, effective, predictable, and profitable investment.

The SM-1997 formulation will be the only approved product for the treatment of sulfur mustard gas injuries in the US and within NATO.

DermDefense’s senior management team includes a formulation expert with decades of experience and a disabled army veteran who has worked with and for the benefit of SM-1997 with the following agencies:

• U.S. Army Medical Research Institute of Chemical Defense (USAMRICD)
• U.S. Army Medical Logistics Command (USAMMA) at Fort Detrick
• Defense Threat Reduction Agency (DTRA)
• Battelle Biomedical
• Biomedical Advanced Research and Development Authority (BARDA)
• National Institutes of Health (NIH)
• Counter Act
• Bundeswehr (German Army)
• Institute of Pharmacology and Toxicology in Munich
• Israel Institute for Biological Research (IIBR)

These agencies, along with several more, are eager to harness the benefits of SM-1997 for our nation’s warriors and our allies who have suffered sulfur mustard gas injuries.